Nilutamide (BioDeep_00000002128)

human metabolite blood metabolite

代谢物信息卡片

5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione

化学式: C12H10F3N3O4 (317.0623376)
中文名称: 尼鲁米特
谱图信息: 最多检出来源 Homo sapiens(blood) 2.67%

分子结构信息

SMILES: CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
InChI: InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

描述信息

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4399; ORIGINAL_PRECURSOR_SCAN_NO 4395
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4426; ORIGINAL_PRECURSOR_SCAN_NO 4421
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4395; ORIGINAL_PRECURSOR_SCAN_NO 4393
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4406; ORIGINAL_PRECURSOR_SCAN_NO 4401
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4403; ORIGINAL_PRECURSOR_SCAN_NO 4401
CONFIDENCE standard compound; INTERNAL_ID 279; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4490; ORIGINAL_PRECURSOR_SCAN_NO 4487
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BB - Anti-androgens
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D000726 - Androgen Antagonists
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C146993 - Androgen Receptor Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
D000970 - Antineoplastic Agents

同义名列表

13 个代谢物同义名

5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-(a,a,a-trifluoro-4-nitro-m-tolyl)hydantoin; Aventis behring brand OF nilutamide; Hoechst brand OF nilutamide; Aventis brand OF nilutamide; Nilutamidum; nilutamide; Nilutamida; Nilandron; Anandron

数据库引用编号

20 个数据库交叉引用编号

ChEBI: CHEBI:7573
KEGG: C08164
KEGGdrug: D00965
PubChem: 4493
HMDB: HMDB0014803
Metlin: METLIN44648
DrugBank: DB00665
ChEMBL: CHEMBL1274
Wikipedia: Nilutamide
chemspider: 4337
CAS: 63612-50-0
MoNA: LU027953
MoNA: LU027955
MoNA: LU027956
MoNA: LU027954
MoNA: LU027952
MoNA: LU027951
PMhub: MS000001886
PubChem: 10364
NIKKAJI: J33.120A

分类词条

Phenylhydantoins

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Tata Sanjay Kanna Sharma, Kuo-Yuan Hwa. Rational design and preparation of copper vanadate anchored on sulfur doped reduced graphene oxide nanocomposite for electrochemical sensing of antiandrogen drug nilutamide using flexible electrodes. Journal of hazardous materials. 2021 05; 410(?):124659. doi: 10.1016/j.jhazmat.2020.124659. [PMID: 33279323]
Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Thangavelu Kokulnathan, Raj Karthik, Shen-Ming Chen, Jeyaraj Vinoth Kumar, Subramanian Sakthinathan. A cerium vanadate interconnected with a carbon nanofiber heterostructure for electrochemical determination of the prostate cancer drug nilutamide. Mikrochimica acta. 2019 07; 186(8):579. doi: 10.1007/s00604-019-3665-5. [PMID: 31352538]
Kumuthini Rajendran, Thangavelu Kokulnathan, Shen-Ming Chen, Joseph Anthuvan Allen, Chinnuswamy Viswanathan, Helen Annal Therese. Nitrogen doped carbon nanofibers loaded with hierarchical vanadium tetrasulfide for the voltammetric detection of the non-steroidal anti-prostate cancer drug nilutamide. Mikrochimica acta. 2019 02; 186(3):141. doi: 10.1007/s00604-019-3251-x. [PMID: 30707311]
R Karthik, R Sasikumar, Shen-Ming Chen, J Vinoth Kumar, A Elangovan, V Muthuraj, P Muthukrishnan, Fahad M A Al-Hemaid, M Ajmal Ali, Mohamed S Elshikh. A highly sensitive and selective electrochemical determination of non-steroidal prostate anti-cancer drug nilutamide based on f-MWCNT in tablet and human blood serum sample. Journal of colloid and interface science. 2017 Feb; 487(?):289-296. doi: 10.1016/j.jcis.2016.10.047. [PMID: 27792936]
Chunkai Wang, Qingjie Zhao, Mireille Vargas, Jeremy O Jones, Karen L White, David M Shackleford, Gong Chen, Jessica Saunders, Alice C F Ng, Francis C K Chiu, Yuxiang Dong, Susan A Charman, Jennifer Keiser, Jonathan L Vennerstrom. Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978). Journal of medicinal chemistry. 2016 12; 59(23):10705-10718. doi: 10.1021/acs.jmedchem.6b01410. [PMID: 27933964]
Shigehiko Takegami, Keisuke Kitamura, Mayuko Ohsugi, Atsuko Konishi, Tatsuya Kitade. 19F Nuclear Magnetic Resonance Spectrometric Determination of the Partition Coefficients of Flutamide and Nilutamide (Antiprostate Cancer Drugs) in a Lipid Nano-Emulsion and Prediction of Its Encapsulation Efficiency for the Drugs. AAPS PharmSciTech. 2016 Dec; 17(6):1500-1506. doi: 10.1208/s12249-016-0495-1. [PMID: 26863891]
Glenn Tisman, April Garcia. Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. Journal of medical case reports. 2011 Aug; 5(?):413. doi: 10.1186/1752-1947-5-413. [PMID: 21867542]
Joon Il Choi, Yun Beom Kim, Seung Ok Yang, Jeong Kee Lee, Tae Young Jung. Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean journal of urology. 2011 Jul; 52(7):461-5. doi: 10.4111/kju.2011.52.7.461. [PMID: 21860766]
Fernand Labrie. Hormonal therapy of prostate cancer. Progress in brain research. 2010; 182(?):321-41. doi: 10.1016/s0079-6123(10)82014-x. [PMID: 20541672]
Anne Cailleux-Bounacer, Vincent Rohmer, Najiba Lahlou, Hervé Lefebvre, Marc Roger, Jean Marc Kuhn. Impact level of dihydrotestosterone on the hypothalamic-pituitary-leydig cell axis in men. International journal of andrology. 2009 Feb; 32(1):57-65. doi: 10.1111/j.1365-2605.2007.00818.x. [PMID: 17931384]
Nicolas Cabaton, Coralie Dumont, Isabelle Severin, Elisabeth Perdu, Daniel Zalko, Mustapha Cherkaoui-Malki, Marie-Christine Chagnon. Genotoxic and endocrine activities of bis(hydroxyphenyl)methane (bisphenol F) and its derivatives in the HepG2 cell line. Toxicology. 2009 Jan; 255(1-2):15-24. doi: 10.1016/j.tox.2008.09.024. [PMID: 18973785]
Yiu-Keung Lau, Manpreet K Chadha, Alan Litwin, Donald L Trump. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. Journal of hematology & oncology. 2008 Nov; 1(?):21. doi: 10.1186/1756-8722-1-21. [PMID: 18986533]
Frederick H Yoon, Sandra L Gardner, Cyril Danjoux, Gerard Morton, Patrick Cheung, Richard Choo. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. The Journal of urology. 2008 Oct; 180(4):1438-43; discussion 1443. doi: 10.1016/j.juro.2008.06.029. [PMID: 18710743]
Hong Sun, Xiao-Lin Xu, Li-Chun Xu, Ling Song, Xia Hong, Jian-Feng Chen, Lun-Biao Cui, Xin-Ru Wang. Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay. Chemosphere. 2007 Jan; 66(3):474-9. doi: 10.1016/j.chemosphere.2006.05.059. [PMID: 16857237]
Jun-ichi Asaka, Tomohiro Terada, Masahiro Okuda, Toshiya Katsura, Ken-ichi Inui. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharmaceutical research. 2006 Apr; 23(4):697-704. doi: 10.1007/s11095-006-9665-2. [PMID: 16550473]
Li-Chun Xu, Hong Sun, Jian-Feng Chen, Qian Bian, Ling Song, Xin-Ru Wang. Androgen receptor activities of p,p'-DDE, fenvalerate and phoxim detected by androgen receptor reporter gene assay. Toxicology letters. 2006 Jan; 160(2):151-7. doi: 10.1016/j.toxlet.2005.06.016. [PMID: 16125883]
Kjetil Ask, Nathalie Décologne, Nana Asare, Jørn A Holme, Yves Artur, Hélène Pelczar, Philippe Camus. Distribution of nitroreductive activity toward nilutamide in rat. Toxicology and applied pharmacology. 2004 Nov; 201(1):1-9. doi: 10.1016/j.taap.2004.04.006. [PMID: 15519603]
Philip M Arlen, James L Gulley, William Dahut. Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans. American journal of therapeutics. 2004 May; 11(3):238-41. doi: 10.1097/00045391-200405000-00015. [PMID: 15133542]
Rachel S Rosenberg Zand, David J A Jenkins, Theodore J Brown, Eleftherios P Diamandis. Flavonoids can block PSA production by breast and prostate cancer cell lines. Clinica chimica acta; international journal of clinical chemistry. 2002 Mar; 317(1-2):17-26. doi: 10.1016/s0009-8981(01)00698-2. [PMID: 11814454]
S A Shain. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer. Molecular urology. 2001; 5(3):121-30. doi: 10.1089/10915360152559602. [PMID: 11690559]
T Battmann, C Branche, F Bouchoux, E Cerede, D Philibert, F Goubet, G Teutsch, M Gaillard-Kelly. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders. The Journal of steroid biochemistry and molecular biology. 1998 Jan; 64(1-2):103-11. doi: 10.1016/s0960-0760(97)00151-9. [PMID: 9569015]
C C Abbou, C Lucas, V Leblanc. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 1997 Dec; 7(6):984-95. doi: NULL. [PMID: 9490144]
J A Smith, P H Lange, R A Janknegt, C C Abbou, A deGery. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. The Journal of urology. 1997 Apr; 157(4):1329-34. doi: . [PMID: 9120932]
A Joual, R Rabii, R Aboutaeib, A el Moussaoui, S Benjelloun. [An unusual presentation of prostate cancer]. Annales d'urologie. 1996; 30(5):262-3. doi: NULL. [PMID: 8975593]
G Verhoeven, L Deboel, J Swinnen, L Rombauts, F Vanderhoydonc, J Rosseels, E Hoeben, W Heyns. Effect of androgens on the germ cell-depleted testes of prenatally irradiated rats. International journal of andrology. 1995 Feb; 18(1):23-34. doi: 10.1111/j.1365-2605.1995.tb00931.x. [PMID: 7540162]
A Decensi, R Torrisi, P Marroni, F Pensa, P Padovani, F Boccardo. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. The Prostate. 1994; 24(1):17-23. doi: 10.1002/pros.2990240106. [PMID: 8290386]
N Warriar, N Pagé, M Koutsilieris, M V Govindan. Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation. The Journal of steroid biochemistry and molecular biology. 1993 Dec; 46(6):699-711. doi: 10.1016/0960-0760(93)90311-j. [PMID: 8274404]
S Akimoto, M Masai, N Kitagawa, T Nakamura, J Shimazaki. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 1993 Mar; 84(3):450-6. doi: 10.5980/jpnjurol1989.84.450. [PMID: 7685840]
D G McLeod. Antiandrogenic drugs. Cancer. 1993 Feb; 71(3 Suppl):1046-9. doi: 10.1002/1097-0142(19930201)71:3+<1046::aid-cncr2820711424>3.0.co;2-m. [PMID: 8428326]
M S Soloway, H Matzkin. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer. 1993 Feb; 71(3 Suppl):1083-8. doi: 10.1002/1097-0142(19930201)71:3+<1083::aid-cncr2820711430>3.0.co;2-1. [PMID: 8428332]
J Fiet, J C Doré, A L Gô, T Ojasoo, J P Raynaud. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. The Prostate. 1993; 23(4):291-313. doi: 10.1002/pros.2990230404. [PMID: 8259343]
P Lointier, D M Wildrick, B M Boman. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer research. 1992 Jul; 12(4):1327-30. doi: . [PMID: 1503430]
J Shimazaki, T Higa, S Akimoto, M Masai, S Isaka. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray. Advances in experimental medicine and biology. 1992; 324(?):269-75. doi: 10.1007/978-1-4615-3398-6_29. [PMID: 1283501]
Y Horsmans, D Lannes, D Larrey, M Tinel, P Letteron, J Loeper, D Pessayre. Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 1991 Dec; 21(12):1559-70. doi: 10.3109/00498259109044405. [PMID: 1785203]
P J Creaven, L Pendyala, D Tremblay. Pharmacokinetics and metabolism of nilutamide. Urology. 1991; 37(2 Suppl):13-9. doi: 10.1016/0090-4295(91)80096-p. [PMID: 1992598]
J D Dhar, B S Setty. Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats. Contraception. 1990 Jul; 42(1):121-38. doi: 10.1016/0010-7824(90)90096-e. [PMID: 2387152]
F H Schröder. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Progress in clinical and biological research. 1990; 359(?):93-103; discussion 105. doi: NULL. [PMID: 2149460]
H Asscheman, L J Gooren, J D Peereboom-Wynia. Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals--experiences with a novel androgen receptor blocker. Clinical and experimental dermatology. 1989 Sep; 14(5):361-3. doi: 10.1111/j.1365-2230.1989.tb02585.x. [PMID: 2612040]
J M Kuhn, T Billebaud, H Navratil, A Moulonguet, J Fiet, P Grise, J F Louis, P Costa, J M Husson, R Dahan. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). The New England journal of medicine. 1989 Aug; 321(7):413-8. doi: 10.1056/nejm198908173210701. [PMID: 2503723]
B Couzinet, G Thomas, J C Thalabard, S Brailly, G Schaison. Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease. Fertility and sterility. 1989 Jul; 52(1):42-50. doi: 10.1016/s0015-0282(16)60786-0. [PMID: 2744186]
D Rouger-Barbier, D Delefosse, R Pamphile, G Goldfarb. [Absence of clinical and biological manifestations after massive absorption of nitulamide]. Journal de toxicologie clinique et experimentale. 1989 Mar; 9(2):77-82. doi: NULL. [PMID: 2810141]
B J Furr. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies. Hormone research. 1989; 32 Suppl 1(?):69-76. doi: 10.1159/000181315. [PMID: 2533159]
M Pavone-Macaluso, V Serretta, C Pavone, C Romano, G Daricello. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate]. Archivos espanoles de urologia. 1989; 42 Suppl 2(?):197-205. doi: NULL. [PMID: 2534783]
S W Lamberts, P Uitterlinden, F H de Jong. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue. Cancer research. 1988 Nov; 48(21):6063-8. doi: . [PMID: 2844399]
L Pendyala, P J Creaven, R Huben, D Tremblay, C Bertagna. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. Cancer chemotherapy and pharmacology. 1988; 22(1):69-76. doi: 10.1007/bf00254185. [PMID: 3396147]
C S Porto, Z P Picarelli, H Hayashi, L C Abreu. Effects of castration and antiandrogens (RU 23908 and cyproterone acetate) on glandulain activity and on the secretory epithelium of the rat submandibular gland. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 1988; 21(3):591-8. doi: . [PMID: 2976284]
B R Rao, A A Geldof, C L van der Wilt, H J de Voogt. Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer. The Prostate. 1988; 13(1):69-78. doi: 10.1002/pros.2990130108. [PMID: 3420036]
L Gooren, T Spinder, J J Spijkstra, H van Kessel, A Smals, B R Rao, M Hoogslag. Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen. The Journal of clinical endocrinology and metabolism. 1987 Apr; 64(4):763-70. doi: 10.1210/jcem-64-4-763. [PMID: 3102546]
S Moorjani, A Dupont, F Labrie, P J Lupien, D Brun, C Gagné, M Giguère, A Bélanger. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism: clinical and experimental. 1987 Mar; 36(3):244-50. doi: 10.1016/0026-0495(87)90183-1. [PMID: 3102895]
H J de Voogt, B R Rao, A A Geldof, L J Gooren, F G Bouman. Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate. The Prostate. 1987; 11(4):305-11. doi: 10.1002/pros.2990110403. [PMID: 2960959]
J P Raynaud, J Fiet, J M Le Goff, P M Martin, M Moguilewsky, T Ojasoo. Design of antiandrogens and their mechanisms of action: a case study (anandron). Hormone research. 1987; 28(2-4):230-41. doi: 10.1159/000180948. [PMID: 3331376]
S Burton, J Trachtenberg. Effectiveness of antiandrogens in the rat. The Journal of urology. 1986 Oct; 136(4):932-5. doi: 10.1016/s0022-5347(17)45134-2. [PMID: 3761464]
R I Huot, S A Shain. Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen. Cancer research. 1986 Aug; 46(8):3775-81. doi: NULL. [PMID: 2942235]
J P Raynaud, D Coussediere, M Moguilewsky, J Pottier, F Labrie. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment]. Bulletin du cancer. 1986; 73(1):36-46. doi: . [PMID: 3779121]
M Moguilewsky, J Fiet, C Tournemine, J P Raynaud. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of steroid biochemistry. 1986 Jan; 24(1):139-46. doi: 10.1016/0022-4731(86)90043-9. [PMID: 3009970]
A Bélanger, A Dupont, F Labrie. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. The Journal of clinical endocrinology and metabolism. 1984 Sep; 59(3):422-6. doi: 10.1210/jcem-59-3-422. [PMID: 6086697]
F Labrie, A Dupont, A Bélanger, J Emond, G Monfette. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 1984 Jun; 81(12):3861-3. doi: 10.1073/pnas.81.12.3861. [PMID: 6427777]
J P Raynaud, C Bonne, M Moguilewsky, F A Lefebvre, A Bélanger, F Labrie. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. The Prostate. 1984; 5(3):299-311. doi: 10.1002/pros.2990050307. [PMID: 6374639]
F Labrie, A Dupont, A Belanger, F A Lefebvre, L Cusan, G Monfette, J G Laberge, J P Emond, J P Raynaud, J M Husson, A T Fazekas. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. Journal of steroid biochemistry. 1983 Jul; 19(1C):999-1007. doi: 10.1016/0022-4731(83)90046-8. [PMID: 6411995]
F Labrie, A Dupont, A Belanger, F A Lefebvre, L Cusan, J P Raynaud, J M Husson, A T Fazekas. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Hormone research. 1983; 18(1-3):18-27. doi: 10.1159/000179775. [PMID: 6411578]
F Labrie, A Dupont, A Belanger, F A Lefebvre, J P Raynaud. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist]. Journal de pharmacologie. 1983; 14 Suppl 3(?):117-35. doi: . [PMID: 6423907]
F Labrie, A Dupont, A Belanger, Y Lacoursiere, J P Raynaud, J M Husson, J Gareau, A T Fazekas, J Sandow, G Monfette. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. The Prostate. 1983; 4(6):579-94. doi: 10.1002/pros.2990040605. [PMID: 6415630]
N Faure, A Lemay, B Laroche, G Robert, R Plante, C Jean, M Thabet, R Roy, A T Fazekas. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. The Prostate. 1983; 4(6):601-24. doi: 10.1002/pros.2990040607. [PMID: 6415632]